Radiopharm Theranostics Limited (RAD) Income Statement
13 Followers
Radiopharm Theranostics Limited Income Statement
Last quarter (Q4 2022), Radiopharm Theranostics Limited's total revenue was $―. In Q4, Radiopharm Theranostics Limited's net income was $―. See Radiopharm Theranostics Limited’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 22
Total Revenue
$ 8.83K
Cost of Revenue
$ ―
Gross Profit
$ 8.83K
Operating Expense
$ 19.93M
Operating Income
$ -19.92M
Net Non Operating Interest Income Expense
$ -9.35M
Other Income Expense
$ -1.03M
Pretax Income
$ -30.29M
Tax Provision
$ 44.40K
Earnings From Equity Interest Net Of Tax
$ ―
Net Income Common Stockholders
$ -30.34M
Basic EPS
$ -0.16
Diluted EPS
$ -0.16
Basic Average Shares
$ 187.49M
Diluted Average Shares
$ 187.49M
Dividend Per Share
$ ―
Total Operating Income As Reported
$ ―
Reported Normalized Basic E P S
$ ―
Reported Normalized Diluted E P S
$ ―
Rent Expense Supplemental
$ ―
Total Expenses
$ ―
Net Income From Continuing And Discontinued Operation
$ -30.34M
Normalized Income
$ -30.34M
Interest Expense
$ 9.35M
EBIT
$ -20.94M
EBITDA
$ -17.96M
Currency in USD
Radiopharm Theranostics Limited Earnings and Revenue History